Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?

Combination therapy is often required in patients with sarcoidosis. Combination of adalimumab with other immunosuppressants, such as methotrexate, leflunomide, azathioprine, or mycophenolate, can be used, with close monitoring of labs (CBC, CMP) and for infections.

Data are limited but the combination of adalimumab and mycophenolate (or other immunosuppressive medications) appears to be safe and effective in various forms of sarcoidosis (Sweiss et al., PMID 24751453, Metyas et al., PMID 24576278, Miller et al., PMID 26828145, Villacis-Nunez & Thakral, PMID 339...

What is the reason the patient needs a DMARD?